: The systems approach to biology and medicine pioneered by the Institute for Systems Biology promises to transform the practice of oncology over the next 2-15 years moving it from a reactive discipline (responding after the patient is sick) to a predictive, preventive and personalize modes. This will be, in part, achieved by using the blood as a window into health and disease. The idea is that biology is mediated by networks of proteins and other molecules that operate within the cell to execute normal functions through the regulation of gene expression. In disease, one or more of these networks becomes perturbed (genetically or environmentally) and the altered patterns of gene expression mediate the disease. These disease-perturbed networks change dynamically with the progression of the diseases, as do their patterns of gene expression. We have identified by computational analyses organ-specific transcripts in the prostate and ovary and again by computational analyses some of these appear to be secreted. Our hypothesis is that at least some of these molecules are secreted into the blood at detectable levels and hence constitute a molecular fingerprint for each organ whose protein components change individually in their levels of expression as one shifts from the normal to a diseased state and as one progresses through the disease state. The power of these proposed organ-specific blood markers is that they let one focus on the changes that occur in just a single organ and that the blood baths all organs and tissues and hence receives secreted protein fingerprints from each. Hence we plan to test the hypothesis that these blood fingerprints become a multiparameter panel of proteins capable of identifying particular diseases and the state of progression of these diseases-and will do using blood proteomics techniques for three different cancers: prostate, ovarian and glioblastoma. We will also test the idea that these blood tests will allow cancer to be detected at a very early stage. The need to extend these blood diagnostic techniques in the future to millions of patients means that new measuring techniques will have to be developed which are ultimately capable of making perhaps 1000 quantitative protein measurements-and doing so rapidly, cheaply, on very small samples and fully automatically. Hence in this grant we will also begin to develop blood-protein measuring devices using microfluidic and nanotechnology approaches that will begin to acquire these features. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA119347-02
Application #
7127647
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Program Officer
Grodzinski, Piotr
Project Start
2005-09-30
Project End
2010-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$3,517,138
Indirect Cost
Name
California Institute of Technology
Department
Chemistry
Type
Schools of Engineering
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Bunck, David N; Atsavapranee, Beatriz; Museth, Anna K et al. (2018) Modulating the Folding Landscape of Superoxide Dismutase?1 with Targeted Molecular Binders. Angew Chem Int Ed Engl 57:6212-6215
Poovathingal, Suresh Kumar; Kravchenko-Balasha, Nataly; Shin, Young Shik et al. (2016) Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics. Small 12:1425-31
Masui, Kenta; Shibata, Noriyuki; Cavenee, Webster K et al. (2016) mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays 38:839-44
Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2016) Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol 33:161-8
Das, Samir; Nag, Arundhati; Liang, JingXin et al. (2015) A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands. Angew Chem Int Ed Engl 54:13219-24
Zuckerman, Jonathan E; Gale, Aaron; Wu, Peiwen et al. (2015) siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther 25:53-64
Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2015) mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathol 25:755-9
Deyle, Kaycie M; Farrow, Blake; Qiao Hee, Ying et al. (2015) A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1. Nat Chem 7:455-62
Hu-Lieskovan, Siwen; Homet Moreno, Blanca; Ribas, Antoni (2015) Excluding T Cells: Is ?-Catenin the Full Story? Cancer Cell 27:749-50
Heath, James R (2015) Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci U S A 112:14436-43

Showing the most recent 10 out of 135 publications